01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Vela Technologies #VELA – Update re. investment in Conduit Pharmaceuticals Inc. August 9, 2024 – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, notes the announcement released by Conduit Pharmaceuticals Inc. (“Conduit”) on 8 August 2024 regarding Conduit entering into an exclusive licence agreement with AstraZeneca for multiple assets to advance potential first-in-class treatments. Vela holds 1,005,760 common shares in Conduit representing 0.46% of Conduit’s issued share capital. At the closing mid-market price of $0.17 on 8 August 2024,…

Continue reading

Vela Technologies #VELA investee co Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets August 8, 2024 – Posted in: Blog, Vela Technologies Plc (VELA)

Vela Technologies #VELA is pleased to note that investee company Conduit Pharmaceuticals has entered into an agreement with AstraZeneca Plc (NASDAQ:AZN) to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators and AZD5904, a myeloperoxidase inhibitor (MPO). AstraZeneca had progressed AZD1656 and AZD5904 through Phase 1 clinical trials. Conduit initially intends to conduct Phase 2 clinical trials on candidates AZD1656 and AZD5658 in 2024 for applications in autoimmune disorders. Under the terms of the License Agreement,…

Continue reading

#HVO hVIVO plc- Share Price November 11, 2022 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, saw the share price rise which was then picked up in the Daily Mail Stock Watch this morning   For further information please contact:   hVIVO plc +44 (0) 20 7756 1300 Yamin ‘Mo’ Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer Liberum…

Continue reading

UK Investor Magazine Podcast -CEO Alan Green discusses AstraZeneca, Georgia Capital and Vela Technologies November 10, 2022 – Posted in: Blog, Uncategorized

Alan Green joins the Podcast as we delve into key markets theme and a number of UK equities. We discuss: AstraZeneca (LON:AZN) Georgia Capital (LON:CGEO) Vela Technologies (LON:VELA) We start by looking at potential catalysts for markets as we move into the winter. AstraZeneca has reported a solid set of third quarter results as the company sees the benefits of higher cancer drug sales. Georgia Capital has been trading at deep discount to NAV and…

Continue reading

Alan Green & Sarah Lowther discuss the market crash, lessons from China, plus an array of stocks including Tiziana Life #TILS & Open Orphan #ORPH on the Total Market Solutions podcast March 15, 2020 – Posted in: Open Orphan (ORPH), Tiziana Life Sciences (TILS)

Friday The 13th & The Weekend Podcast Alan Green Joins Sarah Lowther To Talk All Things Markets During this weekend podcast, and in the wake of a colossal fall, we look at markets which ended the week on Friday the 13th, so far we’ve witnessed an emergency rate cut by the bank of England as the FTSE had its worst day in 33yrs. Alan Green shares some insight on the most recent events surrounding Corona…

Continue reading

Drug companies pay for exclusive access to UK genetic data September 12, 2019 – Posted in: Open Orphan (ORPH)

Dive Brief: Four of the world’s largest drug companies have agreed to pay around $120 million for exclusive access to genetic data on hundreds of thousands of people. Amgen, AstraZeneca, GlaxoSmithKline, and Johnson & Johnson will each have nine months to pour over the first wave of genomic data coming out of UK Biobank before the global research community gets a chance to look at it. That initial wave will be available at the end…

Continue reading